Bavarian Nordic AI Stock Analysis
Want to see BVNRY full AI Analyst Report?
Bavarian Nordic (BVNRY) AI Stock Analysis
Bavarian Nordic
(Other OTC:BVNRY)
Bavarian Nordic's overall score of 79 reflects a financially robust company with strong operational momentum. The primary driver is its fortress-like balance sheet and high profitability, as confirmed by the latest earnings call which highlighted exceptional margins and organic growth. The low P/E ratio further supports an attractive valuation. The main risks tempering the score are the inherent revenue volatility common in biotechnology and a mixed technical picture that shows short-term price weakness despite a longer-term uptrend.
Bavarian Nordic (BVNRY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.77B
- Dividend Yield
- ―
- Average Volume (3M)
- 2,940
- Price to Earnings (P/E)
- 12.0
- Beta (1Y)
- 0.73
- Revenue Growth
- 3.52%
- EPS Growth
- 18.37%
- Country
- US
- Employees
- 1,795
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Bavarian Nordic Business Overview & Revenue Model
Company Description
Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypo...
How the Company Makes Money
Bavarian Nordic primarily makes money by selling vaccines and related services under a mix of government/public-sector procurement, commercial distribution, and partner-enabled sales depending on product and region. Key revenue streams include: (1) P...
Bavarian Nordic Earnings Call Summary
The call was strongly positive overall. Bavarian Nordic reported robust organic growth, very strong Travel Health and rabies performance, high EBITDA margins, strong cash flow, substantial contract coverage and a maintained 2026 outlook. The principal challenges were TBE supply and shelf-life issues, slower-than-expected U.S. Vimkunya uptake, Q4 seasonality and investment needs to support longer-term rabies capacity. These challenges were presented as manageable within the company's current plans.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Bavarian Nordic is maintaining revenue guidance of around DKK 6.1 billion, including approximately DKK 4 billion from Travel Health, while also projecting DKK 3.4 billion from Travel Health and DKK 2.5 billion from Public Preparedness, with an EBITDA margin of around 32%; Public Preparedness is targeting DKK 2.5 billion for the full year versus a normal business base level of DKK 1.5 billion to DKK 2 billion, and Vimkunya has soft guidance of DKK 200 million for the full year. The company expects a lower EBITDA margin in Q4 due to expected lower revenue compared to the previous 9 months and back-end loaded investments into R&D projects and sales and marketing, said it is probably on the conservative side, and expects its manufacturing changes to enable supply into expected demand during '27, although additional investments might be needed beyond '27.
Bavarian Nordic Financial Statement Overview
Summary
The company's financial health is strong, driven by a stellar, nearly debt-free balance sheet (Score: 92) and a return to robust profitability. The income statement shows a healthy 24.5% net margin and 7.3% TTM revenue growth, though historical revenue volatility is a key risk. Cash flow is solid with high-quality earnings, but fluctuating free cash flow due to capex cycles is a minor concern.
Income Statement
78PositiveBalance Sheet
92Very PositiveCash Flow
75Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.08B | 5.93B | 5.72B | 7.06B | 3.15B | 1.90B |
| Gross Profit | 3.14B | 2.81B | 2.82B | 4.53B | 1.70B | 570.32M |
| EBITDA | 2.64B | 1.60B | 1.67B | 2.05B | 84.28M | 85.94M |
| Net Income | 1.56B | 1.32B | 987.98M | 1.48B | -347.38M | -464.77M |
Balance Sheet | ||||||
| Total Assets | 14.72B | 14.95B | 14.41B | 14.35B | 12.39B | 12.09B |
| Cash, Cash Equivalents and Short-Term Investments | 2.36B | 3.33B | 2.18B | 1.87B | 2.85B | 3.72B |
| Total Debt | 131.35M | 130.86M | 128.25M | 145.30M | 1.76B | 1.13B |
| Total Liabilities | 1.51B | 2.08B | 3.00B | 4.01B | 5.24B | 4.71B |
| Stockholders Equity | 13.22B | 12.87B | 11.41B | 10.34B | 7.15B | 7.37B |
Cash Flow | ||||||
| Free Cash Flow | 1.23B | 2.42B | 262.19M | 141.80M | -1.16B | -1.42B |
| Operating Cash Flow | 1.43B | 2.62B | 1.95B | 1.12B | 220.05M | -358.50M |
| Investing Cash Flow | -1.45B | -2.39B | -1.87B | -945.56M | -877.40M | -2.88B |
| Financing Cash Flow | -414.47M | -109.97M | 55.77M | 735.83M | 635.82M | 3.54B |
Bavarian Nordic Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVNRY, the sentiment is Positive. The current price of 11.66 is below the 20-day moving average (MA) of 12.22, above the 50-day MA of 11.54, and above the 200-day MA of 10.24, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 44.30 is Neutral, neither overbought nor oversold. The STOCH value of 2.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BVNRY.
Bavarian Nordic Peers Comparison
Overall Rating
ADMA82.4Outperform- BVNRY79Outperform
ABUS70Outperform
VIR68Neutral
BCRX49Neutral
NVAX43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ADMA | 82Outperform | $2.94B | 17.32 | 42.56% | ― | 6.26% | -10.51% |
| BVNRY | 79Outperform | $2.80B | 12.02 | 11.88% | ― | 3.52% | 18.37% |
| ABUS | 70Outperform | $617.77M | 3.62 | 129.13% | ― | 1142.57% | ― |
| VIR | 68Neutral | $2.08B | -7.97 | -21.38% | ― | 1695.96% | 65.40% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BCRX | 49Neutral | $1.98B | -5.64 | 94.36% | ― | 60.30% | -3028.57% |
| NVAX | 43Neutral | $1.45B | -18.53 | 45.13% | ― | -61.33% | -121.87% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BVNRY | Bavarian Nordic A/S | 11.66 | 2.13 | 22.41% | |
| BCRX | BioCryst Pharmaceuticals | 7.61 | 0.58 | 8.25% | |
| NVAX | Novavax | 8.53 | 1.73 | 25.37% | |
| ABUS | Arbutus Biopharma | 4.09 | -0.45 | -9.91% | |
| ADMA | ADMA Biologics Inc | 13.68 | -1.74 | -11.28% | |
| VIR | Vir Biotechnology, Inc. | 9.96 | 4.47 | 81.42% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026